Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of MS for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s MS forecast will answer the following questions:

  • Of all people diagnosed with MS, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 16 MS patient populations, including the following:

  • Diagnosed prevalent cases of MS
  • Diagnosed prevalent cases of RR-MS
  • Diagnosed prevalent cases of PP-MS
  • Diagnosed prevalent cases of SP-MS
  • Diagnosed prevalent cases of CIS
  • Diagnosed incident cases of MS
  • Diagnosed incident cases of RR-MS
  • Diagnosed incident cases of PP-MS
  • Diagnosed incident cases of CIS
  • Diagnosed prevalent cases of drug-treated MS
  • Diagnosed prevalent cases of drug-treated RR-MS
  • Diagnosed prevalent cases of drug-treated PP-MS
  • Diagnosed prevalent cases of drug-treated SP-MS
  • Diagnosed prevalent cases of drug-treated CIS
  • … and many more (details available on request).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Epilepsy is a complex and heterogeneous neurological disorder that requires individualized management. While the market continues to rely heavily on longestablished generic antiseizure medications…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…
Report
Muscular Dystrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…